The new frontier in oncology is dominated by a powerful and commercially defensible technology: Antibody-drug conjugates. These are not mere drugs; they are highly engineered therapeutic assets built on a strategic trifecta: a precision-targeting antibody, a potent cytotoxic payload, and a sophisticated linker. This combination creates a high barrier to entry, allowing developers to command...